Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 19, Issue 3, 2005, Pages 41-45

  Mystakidou, Kyriaki ^a,b   Katsouda, Emmanuela ^b   Parpa, Efi ^b   Vlavos, Lambros ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bisphosphonates; Bone metastases; Pain relief; Prostate cancer; Zoledronic acid

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CODEINE; FENTANYL; FLUTAMIDE; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; ZOLEDRONIC ACID;

AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CASE REPORT; FEMALE; HUMAN; PATIENT MONITORING; PROSTATE CANCER; QUALITY OF LIFE;

ADENOCARCINOMA; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 27944479578     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1300/J354v19n03_07     Document Type: Article

References (14)

1. Jacobs SC. Spread of prostate cancer to bone. Urology. 1983; 21: 337-44.
2. Kwak C, Seong J, and Park MS, et al. Prognostic Significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
3. Lee CT, and Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24: 389-94.
4. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
5. Demetri GD, Kris M, Wade J, et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-25.
6. Gough IR, Furnival CM, Schilder L, et al. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983; 19: 1161-65.
7. McCormack HM, Horne DJ, Sheather S, et al. Clinical applications of visual analog scales: A critical review. Psychol Med; 1988; 18: 1007-19.
8. Wymenga LFA, Boomsma JHB and Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226-30.
9. Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002; 29: (Suppl 21), 19-27.
10. Smith MR, Eastham J, and Gleason DM, et al. Randomised controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12.
11. Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-8.
12. Terogen O, Heikkila P, Kontinen YT, et al. MMP inhibition and down regulation by bisphosphonates. Ann NY Acad Sci 1999; 878: 453-65.
13. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today 2002; 38: 91-102.
14. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27: 187-92.